Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h16 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...
Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en Europe
02 mai 2024 11h30 HE
|
CROSSJECT
Le contrat couvre désormais un total de 11 pays européens Crossject recevra des paiements d’étape pour un montant total pouvant aller jusqu’à un million d’euros, dès l’obtention des autorisations de...
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
02 mai 2024 11h30 HE
|
CROSSJECT
Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to €1 million in total, upon marketing authorizations Crossject will sell ZEPIZURE®...
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01 mai 2024 08h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
22 avr. 2024 08h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
15 avr. 2024 08h00 HE
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Corp. Presents the Advancement of their Oral Cannabidiol Sulphate Drug Candidate at Epilepsy Therapies Conference
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
26 mars 2024 06h30 HE
|
Praxis Precision Medicines, Inc.
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
Praxis Precision Medicines to Host PRAX-628 Program Update
25 mars 2024 16h01 HE
|
Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h00 HE
|
Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
11 mars 2024 08h00 HE
|
Avenue Therapeutics
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...